Yvonne L. Greenstreet

COO

CEO

Board Member

Equibles does not estimate personal net worth.

Get an email with a short summary when Alnylam Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.

Get ALNY alerts

About Yvonne L. Greenstreet

Yvonne L. Greenstreet is recorded as CEO at Alnylam Pharmaceuticals, Inc. (ALNY) since January 1, 2022, Board Member at Alnylam Pharmaceuticals, Inc. (ALNY) since October 28, 2021 and COO at Alnylam Pharmaceuticals, Inc. (ALNY). The newest filing on record that lists Yvonne L. Greenstreet as CEO at Alnylam Pharmaceuticals, Inc. (ALNY) is dated April 1, 2024. The newest filing on record that lists Yvonne L. Greenstreet as COO at Alnylam Pharmaceuticals, Inc. (ALNY) is dated April 5, 2022. The proxy statement of Alnylam Pharmaceuticals, Inc. reports total compensation of $14,867,600 for Yvonne L. Greenstreet in fiscal 2025, including a base salary of $1,404,200. Disclosed compensation is on record for 9 fiscal years. Alnylam Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Alnylam Pharmaceuticals, Inc. includes Yvonne Greenstreet (CEO and COO), Amy W. Schulman (Chairman and Board Member), Michael Bonney (Chairman) and 7 others.

Affiliation history

Alnylam Pharmaceuticals, Inc. (ALNY)
CEO

Proxy statement

Current
2022-01-01–present

Last confirmed April 1, 2024
Alnylam Pharmaceuticals, Inc. (ALNY)
Board Member

SEC 8-K

Current
2021-10-28–present
Alnylam Pharmaceuticals, Inc. (ALNY)
COO

Proxy statement

Current
Start not stated–present

Last confirmed April 5, 2022

Company network

Alnylam Pharmaceuticals, Inc.

ALNY

Current role

Biotechnology · Healthcare

COO, CEO, Board Member

2021-10-28–present

Leadership on record at Alnylam Pharmaceuticals, Inc.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year	Company	Role	Salary	Bonus	Stock awards	Option awards	Incentive	Other	Total
2025	Alnylam Pharmaceuticals, Inc. (ALNY)	Chief Executive Officer (principal executive officer)	$1,404,200	—	$5,512,500	$4,363,380	$3,562,500	$25,020	$14,867,600
2024	Alnylam Pharmaceuticals, Inc. (ALNY)	Chief Executive Officer (principal executive officer)	$1,253,400	—	$3,625,000	$3,614,400	$2,975,400	$24,770	$11,492,970
2023	Alnylam Pharmaceuticals, Inc. (ALNY)	Chief Executive Officer (principal executive officer)	$975,800	—	$3,375,150	$3,369,000	$1,155,000	$20,720	$8,895,670
2022	Alnylam Pharmaceuticals, Inc. (ALNY)	Chief Executive Officer (principal executive officer)	$850,000	—	—	$2,498,790	$977,500	$262,520	$4,588,810
2021	Alnylam Pharmaceuticals, Inc. (ALNY)	MBChB, MBA Chief Executive Officer (principal executive officer)	$619,100	—	—	$7,341,000	$429,120	$186,000	$8,575,220
2020	Alnylam Pharmaceuticals, Inc. (ALNY)	MBChB, MBA Chief Executive Officer (principal executive officer)	$621,500	—	—	$1,798,843	$434,736	$178,922	$3,034,001
2019	Alnylam Pharmaceuticals, Inc. (ALNY)	MBChB, MBA President and Chief OperatingOfficer	$571,423	—	$460,360	$1,654,494	$370,875	$192,873	$3,250,025
2018	Alnylam Pharmaceuticals, Inc. (ALNY)	MBChB, MBA President and Chief OperatingOfficer	$540,000	—	—	$1,801,063	$216,000	$125,692	$2,682,755
2017	Alnylam Pharmaceuticals, Inc. (ALNY)	MBChB, MBA ChiefOperating Officer	$504,200	—	—	—	$327,730	$152,744	$984,674

Recent activity

No call appearances or filed executive changes recorded yet.